 I-Mab NASDAQ: IMAB, a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced interim results from a multi-center, double blinded, randomized, placebo-controlled, three-arm clinical study NCT04341116 of TJM2 in patients with cytokine release syndrome CRS associated with severe coronavirus disease 2019 COVID-19. 